<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Phe K</submitter><funding>NIAID NIH HHS</funding><pagination>3585-3587</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6296320</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>71(12)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>With increasing rates of infections caused by MDR Gram-negative organisms, clinicians resort to older agents such as colistimethate sodium (CMS) despite a significant risk of nephrotoxicity. Several risk factors for CMS-associated nephrotoxicity have been reported, but they have yet to be validated. We compared the performance of published mathematical models in predicting the risk of CMS-associated nephrotoxicity.&lt;h4>Methods&lt;/h4>In a multicentre, retrospective, cohort study, adult patients (≥18 years of age) were evaluated from five large academic medical centres in the USA. Patients with normal renal function (baseline serum creatinine ≤1.5 mg/dL) who received intravenous CMS for ≥72 h were followed for up to 30 days. The development of nephrotoxicity was as defined by</pubmed_abstract><journal>The Journal of antimicrobial chemotherapy</journal><pubmed_title>Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.</pubmed_title><pmcid>PMC6296320</pmcid><funding_grant_id>K08 AI114883</funding_grant_id><pubmed_authors>Phe K</pubmed_authors><pubmed_authors>Shields RK</pubmed_authors><pubmed_authors>Tam VH</pubmed_authors><pubmed_authors>Luce AM</pubmed_authors><pubmed_authors>Aitken SL</pubmed_authors><pubmed_authors>Lam WM</pubmed_authors><pubmed_authors>Tverdek FP</pubmed_authors><pubmed_authors>Musgrove RJ</pubmed_authors><pubmed_authors>Guervil DJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.</name><description>&lt;h4>Objectives&lt;/h4>With increasing rates of infections caused by MDR Gram-negative organisms, clinicians resort to older agents such as colistimethate sodium (CMS) despite a significant risk of nephrotoxicity. Several risk factors for CMS-associated nephrotoxicity have been reported, but they have yet to be validated. We compared the performance of published mathematical models in predicting the risk of CMS-associated nephrotoxicity.&lt;h4>Methods&lt;/h4>In a multicentre, retrospective, cohort study, adult patients (≥18 years of age) were evaluated from five large academic medical centres in the USA. Patients with normal renal function (baseline serum creatinine ≤1.5 mg/dL) who received intravenous CMS for ≥72 h were followed for up to 30 days. The development of nephrotoxicity was as defined by</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Dec</publication><modification>2025-04-04T22:30:09.777Z</modification><creation>2019-03-27T00:13:15Z</creation></dates><accession>S-EPMC6296320</accession><cross_references><pubmed>27543655</pubmed><doi>10.1093/jac/dkw329</doi></cross_references></HashMap>